Opaleye Management as of Sept. 30, 2023
Portfolio Holdings for Opaleye Management
Opaleye Management holds 40 positions in its portfolio as reported in the September 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Harrow Health (HROW) | 17.9 | $55M | 3.8M | 14.37 | |
| Acelyrin | 13.8 | $42M | 4.1M | 10.17 | |
| Ocular Therapeutix (OCUL) | 6.7 | $20M | 6.5M | 3.14 | |
| Tg Therapeutics (TGTX) | 5.2 | $16M | 1.9M | 8.36 | |
| Rhythm Pharmaceuticals (RYTM) | 4.9 | $15M | 653k | 22.93 | |
| Catalyst Pharmaceutical Partners (CPRX) | 4.6 | $14M | 1.2M | 11.69 | |
| Keros Therapeutics (KROS) | 3.8 | $12M | 360k | 31.88 | |
| Biohaven (BHVN) | 3.7 | $11M | 439k | 26.01 | |
| Crinetics Pharmaceuticals In (CRNX) | 3.6 | $11M | 370k | 29.74 | |
| Eton Pharmaceuticals (ETON) | 3.3 | $10M | 2.4M | 4.17 | |
| Ideaya Biosciences (IDYA) | 2.8 | $8.4M | 312k | 26.98 | |
| Morphosys Sponsored Ads (MOR) | 2.7 | $8.1M | 1.2M | 6.72 | |
| Tela Bio (TELA) | 2.0 | $6.0M | 750k | 8.00 | |
| Edgewise Therapeutics (EWTX) | 1.6 | $5.0M | 875k | 5.73 | |
| Kalvista Pharmaceuticals (KALV) | 1.6 | $4.8M | 500k | 9.63 | |
| Marinus Pharmaceuticals Com New | 1.5 | $4.7M | 584k | 8.05 | |
| Vaxcyte (PCVX) | 1.5 | $4.6M | 90k | 50.98 | |
| Protara Therapeutics Com Stk (TARA) | 1.5 | $4.5M | 2.7M | 1.67 | |
| Urogen Pharma (URGN) | 1.5 | $4.5M | 320k | 14.01 | |
| Geron Corporation (GERN) | 1.3 | $4.1M | 1.9M | 2.12 | |
| Gossamer Bio (GOSS) | 1.3 | $4.0M | 4.8M | 0.83 | |
| 4d Molecular Therapeutics In (FDMT) | 1.3 | $3.9M | 309k | 12.73 | |
| Xoma Corp Del Com New (XOMA) | 1.3 | $3.9M | 275k | 14.09 | |
| Trevi Therapeutics (TRVI) | 1.2 | $3.7M | 1.7M | 2.18 | |
| Liquidia Corporation Com New (LQDA) | 1.2 | $3.6M | 571k | 6.34 | |
| Larimar Therapeutics (LRMR) | 1.1 | $3.4M | 849k | 3.95 | |
| Nyxoah S A SHS (NYXH) | 1.0 | $3.1M | 442k | 7.05 | |
| Gossamer Bio Note 5.000% 6/0 | 1.0 | $3.1M | 8.0M | 0.39 | |
| Iovance Biotherapeutics (IOVA) | 0.9 | $2.8M | 610k | 4.55 | |
| Applied Therapeutics (APLT) | 0.7 | $2.2M | 893k | 2.49 | |
| Igm Biosciences (IGMS) | 0.7 | $2.2M | 261k | 8.35 | |
| Codexis (CDXS) | 0.7 | $2.1M | 1.1M | 1.89 | |
| Verastem Com New (VSTM) | 0.6 | $1.7M | 211k | 8.13 | |
| Precigen (PGEN) | 0.4 | $1.3M | 929k | 1.42 | |
| Tracon Pharmaceuticals Com New | 0.3 | $848k | 4.8M | 0.18 | |
| Biodesix (BDSX) | 0.2 | $752k | 456k | 1.65 | |
| Xeris Pharmaceuticals (XERS) | 0.2 | $725k | 390k | 1.86 | |
| Fortress Biotech | 0.2 | $581k | 2.0M | 0.29 | |
| Kezar Life Sciences | 0.2 | $506k | 425k | 1.19 | |
| Relmada Therapeutics (RLMD) | 0.0 | $90k | 30k | 3.00 |
